ClinicalTrials.gg
RecruitingNCT07540221XPERTUpdated Nov 10, 2026

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

A Phase 3 interventional study of Gamunex-C and Xembify in CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), sponsored by Grifols Therapeutics LLC. Recruiting at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 10, 2026First site in Romania6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.

Planned enrollment
29th of 42
40 · median 74
Started
2026
with 3 others
Phase 3
15 of 55
8 open now
Primary completion
2027-12
later than 12 of 24 live
Registered
55th of 55
by date
Lead sponsor
2 of 55
Grifols Therapeutics LLC

Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 29th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2026, is one of 15 in phase 3, reaches primary completion later than 12 of the 24 other live ones, and was the 55th registered.

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Open to participants now

20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, or all of them as a file.
02

Study summary

The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP.

Participants with CIDP will first have up to 28 days of screening to make sure they can join the study. Those who qualify will then start a 19-week treatment period with Gamunex-C. During this period, they will receive Gamunex-C through a vein once every 3 weeks, for a total of 7 doses. Approximately, one week after their last Gamunex-C dose, they will begin a 16-week treatment period with XEMBIFY under the skin, once a week for a total of 16 doses. Blood samples will be collected during both treatment periods to measure IgG level in the blood.

03

Conditions studied

  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Keywords

  • XEMBIFY
  • CIDP
  • IgG
  • Gamunex-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have typical CIDP or a CIDP variant according to the 2021 criteria established by the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS). The level of diagnostic certainty may be CIDP or possible CIDP.
  • Participants ≤ 90 kg in body weight and requiring an IGIV dose equivalent to 0.3-1.0 g/kg every three weeks (Q3W) inclusive and between 20-90 g of IGIV Q3W inclusive.
  • Clinically stable on IGIV, defined as no recent change in CIDP treatment or experienced a CIDP relapse requiring treatment, within 12 weeks prior to Screening and through baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of polyneuropathy of any other cause (including multifocal motor neuropathy; monoclonal gammopathy of uncertain significance with anti-myelin-associated glycoprotein IgM antibodies; hereditary demyelinating neuropathy; polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome; lumbosacral radiculoplexus neuropathy; polyneuropathy associated with diabetes mellitus; polyneuropathy associated with systemic illnesses; or drug or toxin induced polyneuropathy).
  • Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study such as the following:

    1. current or history of allogeneic bone marrow/stem cell transplant,
    2. cardiac insufficiency ( classes III/IV), cardiomyopathy, significant cardiac arrhythmia requiring treatment, unstable or advanced ischemic heart disease, congestive heart failure or severe hypertension
    3. chronic kidney disease stage IV or V
    4. an acquired medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia ( less than 1000/µL [1.0 × 10\^9/L]), or (HIV) infection/acquired immune deficiency syndrome
    5. known bleeding disorders
    6. severe skin disease at the planned injection sites
    7. alcohol, drug or medication abuse, or
    8. other disorders where IGSC therapy would be during the study.
  • History of a thrombotic episode (including deep vein thrombosis, known hypercoagulable state, myocardial infarction, pulmonary embolism, or thromboembolic stroke)
  • Known allergic or other severe adverse reactions to blood products including intolerability to previous IVIG up to 1 g/kg Q3W, history of hemolysis after IVIG infusion, aseptic meningitis, recurrent severe headache, , or severe generalized skin reaction
  • Has had a CIDP relapse requiring treatment modification within 12 weeks prior to Screening or between Screening and baseline visit
  • Treatment with any of the following:

    1. alemtuzumab or rituximab within 12 months of Screening.
    2. cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or fragment crystallizable receptor (FCRn) blockers, within six months of Screening
    3. plasma exchange or complement inhibitors within three months of Screening.
    4. changes to the following treatment within three months of Screening: methotrexate, azathioprine, or mycophenolate or any other within six months of Screening
    5. participants on ≥ 20 mg/day prednisone equivalent. Participants on low dose corticosteroids (\< 20 mg/day prednisone equivalent) may be enrolled if dose has been stable over the last three months prior to Screening and the dosage is not likely to be adjusted during the duration of the trial (inhaled or topical corticosteroids are allowed).
  • Participants requiring an IGIV dose equivalent to:

    1. greater than 1.0 g/kg every three weeks (Q3W) or
    2. less than 0.3 g/kg Q3W or
    3. greater than 90 g of IGIV Q3W or
    4. less than 20 g of IGIV Q3W.
  • Known IgA deficient patients with known antibodies against IgA
  • Known significant proteinuria (≥ 3+ or known urinary protein loss >1 g/24 hours or nephrotic syndrome), acute renal failure, are on dialysis, and/or have severe renal impairment on Screening laboratory testing (blood urea nitrogen [BUN] > 3 times the [ULN] or creatinine more than 1.5 times ULN).
  • Screening values of (AST) or alanine aminotransferase (ALT) levels exceeding ≥ 2.5 times the ULN for the expected normal range for the testing laboratory.
  • levels \< 10 g/dL at Screening.
  • Current administration of anti-coagulation therapy which would make IGSC administration inadvisable per investigator judgement (i.e., vitamin K antagonists, nonvitamin K antagonist oral anticoagulants [e.g., dabigatran etexilate targeting Factor IIa, rivaroxaban, edoxaban, and apixaban targeting Factor Xa], and parenteral anticoagulants [e.g., fondaparinux]).
  • Known hyperviscosity syndrome.
  • Known HIV, chronic virus (HBV), or chronic virus (HCV) infection.
  • Participation in another clinical trial within 30 days or if known, 5 half-lives of the interventional product prior to Screening (observational studies without investigative treatments [non-interventional] are permitted).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Gamunex-C (IGIV-C 10%)

    During the IV Phase, participants will receive Gamunex-C 1 g/kg, up to a maximum dose of 90 g, every 3 weeks for a total of seven doses. Gamunex-C may be administered over 1 day or divided into 2 consecutive daily doses of 0.5 g/kg each, except for dose #6, which will be administered as a single 1g/kg dose.

    Biological: Gamunex-C

  • Experimental
    Xembify (IGSC 20%)

    Approximately 7 to 10 days after the last Gamunex-C dose, participants will enter a 16-week SC Phase, where they will receive XEMBIFY 0.456 g/kg once weekly for a total of 16 doses, up to a maximum dose of 41 g.

    Biological: Xembify

Interventions

  • BiologicalGamunex-C

    Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (IGIV-C 10%)

  • BiologicalXembify

    Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%)

06

What researchers measure

Primary outcomes

  1. AUC in the IV Phase: Steady-state area under the concentration-time curve (AUC) of total IgG over a 3-week intravenous dosing interval (τ) (i.e., AUC(0-21days) in participants with CIDP

    Time frame: Week 1 to 19 of IV Phase

  2. AUC in the SC Phase: Steady-state AUC of total IgG over a weekly SC dosing interval (τ) (i.e., AUC(0-7days)) in participants with CIDP

    Time frame: Week 1 to 16 of SC Phase

Secondary outcomes

  1. Steady-state mean trough (pre-dose) concentration of total IgG following IV administration of Gamunex-C 10% every 3 weeks SC administration of Xembify 20% once weekly

    Time frame: Day 1 through End of Study Visit (approximately 35 weeks)

07

Study locations

15 of 16 sites recruiting
  • GC2402 Study Site 104
    Rancho Mirage, California 92270, United States
    Recruiting
  • GC2402 Study Site 109
    Coral Springs, Florida 33155, United States
    Recruiting
  • GC2402 Study Site 105
    Miami, Florida 33067, United States
    Withdrawn

    Not enrolling at this site.

  • GC2402 Study Site 103
    Port Charlotte, Florida 33952, United States
    Recruiting
  • GC2402 Study Site 110
    New York, New York 10003, United States
    Recruiting
  • GC2402 Study Site 114
    Fayetteville, North Carolina 28304, United States
    Recruiting
  • GC2402 Study Site 111
    Cordova, Tennessee 38018, United States
    Recruiting
  • GC2402 Study Site 115
    Houston, Texas 77074, United States
    Recruiting
  • GC2402 Study Site 106
    Sherman, Texas 75092, United States
    Recruiting
  • GC2402 Study Site 401
    Hradec Králové, 50002, Czechia
    Recruiting
  • GC2402 Study Site 206
    Bydgoszcz, 85-065, Poland
    Recruiting
  • GC2402 Study Site 203
    Katowice, 40-123, Poland
    Recruiting
  • GC2402 Study Site 201
    Krakow, 31-870, Poland
    Recruiting
  • GC2402 Study Site 205
    Wroclaw, 50-417, Poland
    Recruiting
  • GC2402 Study Site 207
    Wroclaw, 54-239, Poland
    Recruiting
  • GC2402 Study Site 302
    Târgu Mureş, 540140, Romania
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 20, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Romania
Show 6 added (3 Poland, 2 United States, 1 Romania)
  • GC2402 Study Site 114 · Fayetteville, United States
  • GC2402 Study Site 115 · Houston, United States
  • GC2402 Study Site 201 · Krakow, Poland
  • GC2402 Study Site 205 · Wroclaw, Poland
  • GC2402 Study Site 302 · Târgu Mureş, Romania
  • GC2402 Study Site 207 · Wroclaw, Poland
across 2 updates, Oct 9, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    1 site added
    Show site
    • GC2402 Study Site 207 · Wroclaw, Poland
    + 1 other change: verification date
  2. Oct 9, 2026
    5 sites added — first site in Romania
    Show 5 added (2 United States, 2 Poland, 1 Romania)
    • GC2402 Study Site 114 · Fayetteville, United States
    • GC2402 Study Site 115 · Houston, United States
    • GC2402 Study Site 201 · Krakow, Poland
    • GC2402 Study Site 205 · Wroclaw, Poland
    • GC2402 Study Site 302 · Târgu Mureş, Romania
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540221
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 2, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Sarah Duggan
Contact
sarah.duggan@grifols.com
+353 87 429 2411
Olga Titova
Contact
olga.titova@grifols.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion